PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure

International Journal of Radiation Oncology Biology Physics

Volumn 83, Issue 2, 2012, Pages 600-607

  Ko, Eric C ^a   Stone, Nelson N ^a   Stock, Richard G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Prostate cancer; PSA failure; PSA kinetics; PSA nadir

Indexed keywords

ANTIGENS; DISEASES; MULTIVARIANT ANALYSIS; ONCOLOGY; PATHOLOGY; UROLOGY;

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; EXTERNAL BEAM RADIATION THERAPY; FREEDOM FROM BIOCHEMICAL FAILURES; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; PSA FAILURE; PSA NADIR;

RADIOTHERAPY;

PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; DATA BASE; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR;

EID: 84861097286     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.07.009     Document Type: Article

References (18)

1. M. Maffezzini, A. Bossi, and L. Collette Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer Eur Urol 51 2007 605 613 (Pubitemid 46097288)
2. C.R. King, J.C. Presti, and J.D. Brooks Postoperative prostate-specific antigen velocity independently predicts for failure of salvage radiotherapy after prostatectomy Int J Radiat Oncol Biol Phys 70 2008 1472 1477 (Pubitemid 351417751)
3. D.E. Soto, R.R. Andridge, and C.C. Pan In patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free interval Int J Radiat Oncol Biol Phys 71 2008 1295 1301
4. A. Thompson, M. Keyes, and T. Pickles Evaluating the Phoenix definition of biochemical failure after (125)I prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounces? Int J Radiat Oncol Biol Phys 78 2010 415 421
5. C.M. Iannuzzi, R.G. Stock, and N.N. Stone PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer Radiat Oncol Investig 7 1999 30 35 (Pubitemid 29078862)
6. R. Takamiya, V. Weinberg, and C.D. Young A zero PSA slope in posttreatment prostate-specific antigen supports cure of patients with long-term follow-up after external beam radiotherapy for localized prostate cancer Int J Radiat Oncol Biol Phys 56 2003 1073 1078 (Pubitemid 36794040)
7. S.X. Cavanaugh, P.A. Kupelian, and C.D. Fuller Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: Prognostic value of a time-and-PSA threshold model Cancer 101 2004 96 105 (Pubitemid 38812428)
8. S.X. Cavanaugh, C.D. Fuller, and P.A. Kupelian Time and PSA threshold model prognosticates long-term overall and disease-specific survival in prostate cancer patients as early as 3 months after external beam radiation therapy Prostate Cancer Prostatic Dis 8 2005 353 358 (Pubitemid 43078171)
9. M. Pinkawa, K. Fischedick, and M.D. Piroth Prostate-specific antigen kinetics after brachytherapy or external beam radiotherapy and neoadjuvant hormonal therapy Urology 69 2007 129 133 (Pubitemid 46161683)
10. M. Pinkawa, M.D. Piroth, and R. Holy Prostate-specific antigen kinetics following external-beam radiotherapy and temporary (Ir-192) or permanent (I-125) brachytherapy for prostate cancer Radiother Oncol 96 2010 25 29
11. G.J. Kubicek, M. Naguib, and S. Redfield PSA decrease during combined-modality radiotherapy predicts for treatment outcome Int J Radiat Oncol Biol Phys 78 2010 759 762
12. R.G. Stock, N.N. Stone, M.F. Wesson, and J.K. DeWyngaert A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation Int J Radiat Oncol Biol Phys 32 1995 219 225
13. J.A. Cesaretti, N.N. Stone, and V.M. Skouteris Brachytherapy for the treatment of prostate cancer Cancer J 13 2007 302 312
14. N.N. Stone, R.G. Stock, J.A. Cesaretti, and P. Unger Local control following permanent prostate brachytherapy: Effect of high biologically effective dose on biopsy results and oncologic outcomes Int J Radiat Oncol Biol Phys 76 2010 355 360
15. G.K. Zagars Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy J Urol 152 1994 1786 1791 (Pubitemid 24322630)
16. F.A. Critz, W.H. Williams, and C.T. Holladay Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques Urology 54 1999 968 971
17. P.D. Grimm, J.C. Blasko, and J.E. Sylvester 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy Int J Radiat Oncol Biol Phys 51 2001 31 40 (Pubitemid 32758858)
18. D.S. Lamb, J.W. Denham, and D. Joseph A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: Analysis of data from the TROG 96.01 randomized trial Int J Radiat Oncol Biol Phys 79 2011 385 391